some patient series suggest an increased risk of cancer among patients with scleroderma, there are no population based studies to support this association. A population based follow up study was therefore carried out of 233 patients with scleroderma from the six-county Uppsala health care region of Sweden for the time period 1955-84. Methods-Using the inpatient registry for the Uppsala health care region, all patients with scleroderma were identified. Their unique identification codes were then used to perform a record linkage with the National Cancer Registry. Expected cancer rates were determined using the age and gender specific rates for the Uppsala health care region. Results-The standardised incidence ratio (SIR) for all cancers among these patients was significantly increased (SIR=2.4; 95% CI=15 to 3.6). The SIRs for lung cancer (SIR=7*8; 95% CI=2-5 to 18.2) and non-Hodgkin's lymphoma (SIR=9-6; 95% CI=l.l to 34.5) (table 2) . The overall cancer SIR for the scleroderma cohort was 2-4 (95% confidence interval (CI) 1-5 to 3 6), indicating a significantly increased rate of malignancy among patients with this disease. The overall cancer risk was increased in both men (SIR= 1 8) and women (SIR=2 9), though only among women was the increased risk statistically significant.
For individual cancer sites there were statistically significant excesses of cancer of the lung (SIR=7-8; 95% CI 2-5 to 18&2) and haematopoietic cancers due to an increased risk of non-Hodgkin's lymphoma (SIR=9-6; 95% CI 1 1 to 34 5) (table 2). Of the five lung cancers, one was an adenocarcinoma, three were squamous cell cancers, and one was an unspecified epithelial cancer.
To correct for possible selection bias, the data were analysed excluding the first year after diagnosis. Significant increases still remained for overall cancer occurrence and for lung cancer (table 3) . The excess of non-Hodgkin's lymphoma also remained, though it was no longer statistically significant as it was based on only one case. To evaluate bias further we restricted the cohort to patients whose primary discharge diagnosis was scleroderma and found no difference in risk estimates for cancers overall, lung cancer, or non-Hodgkin's lymphoma. Patients with scleroderma in this cohort did not have a significantly increased risk of breast, ovarian, or oesophageal cancers, though the power to detect excess risk for these tumours was limited.
Discussion
Several early studies concluded that there was no increase in malignancy among patients with scleroderma, but most of these were reports on the prevalence of cancer at initial presentation in tertiary referral centres4 6 13 or the prevalence of malignancies at necropsy among patients with scleroderma. 14-6 The risk of cancer cannot be assessed in these studies because no appropriate comparison data were available to calculate rates. In one study in which risk was calculated, Black et all7 found no increased incidence of cancer among 27 patients with scleroderma from a single centre in Australia.
In contrast, Roumm and Medsger5 reported an increased risk for cancer of 1 8 among 262 patients with scleroderma from a tertiary care hospital in Pittsburgh compared with expected rates. This increase was largely accounted for by an increase in lung cancer (relative risk 4 
4).
Another follow up study,'8 as well as prevalence'3 and necropsy data,'6 have suggested that the risk of lung cancer may be increased among patients with scleroderma. Our data support this association. Although alveolar cell carcinoma has been linked with scleroderma in clinical reports,'9 20 squamous cell cancers predominated in our patients. Pulmonary fibrosis associated with scleroderma may increase the risk of lung cancer. Growth factors implicated in fibrosis may be mitogenic and cause excess cellular division resulting in transformation.2' Alternatively, changes in the extracellular matrix, which plays an important part in growth and differentiation, may affect the behaviour of normal cells. 22 We observed a suggestive excess risk of nonHodgkin's lymphoma among patients with scleroderma. No increase of non-Hodgkin's lymphoma was found in two earlier follow up studies of patients,5 17 nor has an excess of scleroderma been reported in case-control studies of non-Hodgkin's lymphoma.23 26 Patients with other connective tissue disorders, however, notably rheumatoid arthritis and Sjogren's syndrome, have shown an excess risk of non-Hodgkin's lymphoma.27 29 34 and in a large series4 of patients with scleroderma. We did not observe any excess of breast The advantages of this study include its population based nature and the near complete coverage of the cancer registry and the patient discharge registry, which includes patients admitted to hospital anywhere in Sweden with scleroderma who lived in the Uppsala region during the study period. On the other hand, the patient cohort was relatively small and included only those patients with a hospital diagnosis. These patients may be older and have more severe scleroderma than patients not admitted to hospital. The average age at entry to the cohort, 57 9 years, suggests that the patients are older than the 45-54 year old age group which is the most common age group at time of diagnosis.' The ratio of women to men in our cohort, 1 6:1, is lower than previously reported, but more in line with the sex ratios found among older patients.3 Despite these problems, we believe that this study may provide useful epidemiological clues.
In summary, we have observed an increased risk of lung cancer and a suggestive excess of non-Hodgkin's lymphoma in a cohort of patients with scleroderma. Larger studies are needed to confirm these findings and to evaluate other site specific cancers thought to be in excess among these patients.
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